The contribution of lncRNAs to tumour progression and the regulatory mechanisms driving their expression are areas of intense investigation. Here, we characterize the binding of heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) to a nucleic acid structural element located in exon 12 of PNUTS (also known as PPP1R10) pre-RNA that regulates its alternative splicing. HnRNP E1 release from this structural element, following its silencing, nucleocytoplasmic translocation or in response to TGFβ, allows alternative splicing and generates a non-coding isoform of PNUTS. Functionally the lncRNA-PNUTS serves as a competitive sponge for miR-205 during epithelial-mesenchymal transition (EMT). In mesenchymal breast tumour cells and in breast tumour samples, the expression of lncRNA-PNUTS is elevated and correlates with levels of ZEB mRNAs. Thus, PNUTS is a bifunctional RNA encoding both PNUTS mRNA and lncRNA-PNUTS, each eliciting distinct biological functions. While PNUTS mRNA is ubiquitously expressed, lncRNA-PNUTS appears to be tightly regulated dependent on the status of hnRNP E1 and tumour context.
Breast cancer in females and lung cancer in males are the most frequently diagnosed cancers and the leading cause of cancer death worldwide 1 . Although metastasis is the overwhelming cause of mortality in patients with solid tumours, the molecular and cellular mechanisms that drive tumour cells to become metastatic remain largely unknown [2] [3] [4] .
Non-coding RNAs have recently emerged as key mediators of tumour progression through their regulation of both oncogenic and tumour-suppressive pathways 5, 6 . Long non-coding RNAs (lncRNAs) have been implicated in cellular processes such as proliferation, apoptosis, migration and cell invasion and their dysregulated expression has been observed in various human cancers 7, 8 . Despite these recent findings, the regulatory role of lncRNAs in mediating these cellular processes and in cancer development remains an area of active investigation and the subject of controversy 9, 10 .
Epithelial-mesenchymal transition (EMT) is a developmental process aberrantly reactivated during tumour progression of epithelial cells and contributes to resistance of both conventional and targeted therapies 11, 12 . We have previously demonstrated that posttranscriptional regulation of gene expression plays an important role in EMT, especially during TGFβ-mediated EMT 13, 14 . We described a transcript-selective translational regulatory pathway involving the binding of hnRNP E1 protein to a BAT structural element (for TGF-beta-activated translational element) located in the 3 -UTR of transcripts involved in EMT-related tumour progression 13, 15 . In addition, hnRNP E1 protein was previously described to regulate other critical cellular processes such as transcription, messenger RNA stability, transport and splicing 16 .
Alternative splicing regulates over 90% of multi-exon proteincoding genes in humans 17 and hnRNP E1 is well documented for its repressive role in this process. HnRNP E1 represses tumour cell invasion by inhibiting the alternative splicing of CD44 (ref. 18 ) and binds to the growth hormone receptor pseudoexon to prevent its usage, thus allowing expression of a functional protein 19 .
Here we report the binding of hnRNP E1 to an alternative splicing site in the pre-RNA of PNUTS to control the generation of an alternative spliced isoform of PNUTS that we describe as a lncRNA involved in EMT-related tumour progression. The study reveals that the PNUTS pre-RNA transcript serves as a bifunctional RNA capable of generating PNUTS mRNA or lncRNA-PNUTS in an hnRNP-E1dependent and cell-context-dependent manner.
RESULTS
The predicted lncRNA-PNUTS is upregulated following hnRNP E1 loss and during tumour cell progression Using an hnRNP E1 knockdown-induced EMT model in NMuMG cells ( Supplementary Fig. 1a ), we performed an Affymetrix array analysis and identified PNUTS pre-RNA as downregulated following Regular splice site 3′ ASS Figure 1 PNUTS alternative splicing occurs following hnRNP E1 loss and is increased in mesenchymal tumour cells. (a) Heat map of Affymetrix array data showing expression levels (log 2 fold) of either PNUTS pre-RNA or PNUTS mRNA in control (Cont.) or hnRNP E1 knockdown (E1KD) NMuMG cells. The data were generated from triplicate samples. * Two distinct probes were used to target the spliced PNUTS RNA. (b) NCBI database accession numbers of PNUTS mRNA and the PNUTS predicted lncRNA isoform in human. (c) Validation by RT-PCR analysis with primers specific to PNUTS isoforms of alternative PNUTS gene processing following hnRNP E1 knockdown in the human A549 cell line. (d) Left, PNUTS isoform expression levels analysed by RT-PCR in human breast tumour samples (T) or non-tumour counterparts (NT). Right, quantitative RT-PCR analysis of lncRNA-PNUTS, ZEB1 and ZEB2 expression in 24 human breast tumour samples. Relative expression levels of transcripts were calculated using the Ct method, normalizing to GAPDH. Correlations between transcript expression levels were evaluated using the Pearson correlation coefficient test. (Linear regression, df = 24-2, a Pearson score > 0.515 and P < 0.05 was considered as significant). Source data are available in Supplementary  Table 2 . (e) PNUTS isoform expression screening by RT-PCR analysis in MCF10a mammary gland epithelial cells and MDA-MB-468 breast cancer epithelial cells, or in the metastasis progression model of the MDA-MB-231 mesenchymal cell line (MDA-231, BOM-1833, LM2-4175). E-cadherin (CDH1) was used as an epithelial marker while vimentin (VIM) and ZEB1 were used as mesenchymal-cell-specific markers. (f) Map of PNUTS isoforms acquired by sequence alignment and drawn by using fancyGene online software. (g) Schematic representation of the alternative splicing region of the PNUTS variants (ASS, alternative splicing site). (h) RT-PCR amplification of the exon 11-exon 12 junction encompassing the predicted alternative splicing site using intron-flanking PCR primers as indicated in g. (i) Northern blot analysis of the expression levels of both the PNUTS mRNA and lncRNA isoforms in control (SCR) or hnRNP E1 knockdown (E1KD) A549 cell clones.
hnRNP E1 knockdown while the associated PNUTS mRNA remained relatively unaffected ( Fig. 1a ), suggesting a differential processing of PNUTS pre-RNA. Interestingly, the human PNUTS gene is described to encode two sequenced variants. While variant 1 encodes the wellcharacterized PNUTS mRNA, variant 2 has not been investigated and is predicted to be a lncRNA ( Fig. 1b) . We validated the differential processing of PNUTS pre-RNA by PCR with reverse transcription (RT-PCR) analysis with primers specific to PNUTS isoforms ( Fig. 1c and Supplementary Fig. 6 ).
The biological significance of PNUTS pre-RNA differential processing is demonstrated in human breast tumour samples ( Fig. 1d ) and in breast cancer cell lines (Fig. 1e ). We observed upregulation of the predicted lncRNA-PNUTS in breast tumour samples and a correlation between ZEB1/ZEB2 mesenchymal marker expression and lncRNA-PNUTS ( Fig. 1d ) but not with the PNUTS mRNA (Supplementary Fig. 1b ). We also observed a correlation between lncRNA-PNUTS expression and the epithelial/mesenchymal status of breast cancer cells. In the more mesenchymal MDA-MB-231 cell line, and its metastatic bone (BOM-1833) and metastatic lung (LM2-4175) derivatives 20 , we observed increased expression of the predicted lncRNA-PNUTS correlating with the expression of the mesenchymal markers vimentin and Zeb1; whereas, in the more epithelial MCF10a and MDA-MB-468 cell lines expressing the epithelial marker E-cadherin, there was less expression of the predicted lncRNA (Fig. 1e ).
The NCBI database predicts the generation of lncRNA-PNUTS as a result of the removal of 61 bases in the 5 -region of exon 12 leading to a break in the open reading frame of the transcript (Fig. 1f,g) . By RT-PCR, using flanking primers ( Supplementary Fig. 6 ), we demonstrated the existence of an alternative splice product of the expected size ( Fig. 1h ) and validated the alternative splicing model by sequencing ( Supplementary Fig. 1c ). The alternative splice site is also identified in the mouse ( Supplementary Figs 1d,e ), and northern blot validated the size of the full-length lncRNA-PNUTS and its upregulation following hnRNP E1 knockdown ( Fig. 1i ).
hnRNP E1 prevents the splicing of the lncRNA-PNUTS isoform by binding to a BAT structural element located at the alternative splice site
The alternative splice site in exon 12 of the PNUTS gene is also predicted in silico by the HSF finder 21 (Supplementary Fig. 2a ). Interestingly, this alternative site has a higher consensus splice site value (91.74) than the regular splice site (79.38) used to generate the PNUTS mRNA ( Supplementary Fig. 2a ), suggesting the existence of an inhibitory mechanism of alternative splicing site utilization. Since hnRNP E1 is a known repressor of alternative splicing 18, 19 and its knockdown results in upregulation of lncRNA-PNUTS, we postulated that it is an endogenous repressor of PNUTS pre-RNA splicing.
We previously described that hnRNP E1 binds to a consensus BAT element, consisting of a stem-loop structure with an asymmetric bulge located in the 3 -UTR of RNAs 13, 22 . An analysis of the secondary structure of the PNUTS alternative splicing site in human and mouse sequences revealed the existence of a similar evolutionarily conserved BAT-like element encompassing the alternative splicing site ( Fig. 2a and Supplementary Fig. 1f ). We thus designed PNUTS BAT alternative splicing site RNA probes, wild type or mutated, to perform RNA electromobility shift assays and validated the direct and specific binding of hnRNP E1 to the structural element. Combinations of whole-cell lysates from A549 cells with the wild-type probe show a significant gel shift that is abolished by using either the mutant probe or whole-cell lysates prepared from A549 cells silenced for hnRNP E1 (Fig. 2b ). Direct binding was further validated using recombinant hnRNP E1 protein ( Fig. 2b ). To test whether hnRNP E1 removal from the BAT alternative splicing site can mediate alternative splicing, we used two methods to induce its dissociation from RNA. First, on the basis of our earlier demonstration that TGFβ-induced Akt2 phosphorylation of hnRNP E1 leads to its loss of binding and release from the BAT element 13, 15 , we treated cells with TGFβ and observed alternative splicing occurring in both A549 and MDA-468 cells, generating the lncRNA-PNUTS isoform within 30 min and persisting for ∼3 h ( Fig. 2c and Supplementary Fig. 1g ). Second, since inhibition of transcription with RNA polymerase inhibitors results in cytoplasmic accumulation of many splicing factors 23 , we treated cells with actinomycin D (ActD) and performed both immunofluorescence analysis and cell fractionation to investigate hnRNP E1 localization following transcriptional inhibition ( Fig. 2d,e ). We observed that ActD induced the release of hnRNP E1 from pre-RNAs and its nuclear/cytoplasmic shuttling, resulting in cytoplasmic accumulation ( Fig. 2d,e ). Concomitantly, cytoplasmic accumulation of hnRNP E1, in response to ActD, results in a strong induction of PNUTS alternative splicing that is not observed in hnRNP-E1-silenced cells (Fig. 2f ). These results suggest that hnRNP E1 binding to the PNUTS pre-RNA alternative splicing site mediates an inhibitory effect on alternative splicing. To further validate this splicing model, we designed an antisense oligonucleotide (ASO) to the alternative splicing site to prevent its utilization. As shown in A549 cells ( Fig. 2g ), the ASO prevents, in a concentration-dependent manner, the alternative splicing induced by hnRNP E1 release following ActD treatment.
PNUTS alternative splicing product is a cytosolic and nuclear lncRNA PNUTS mRNA encodes the PNUTS protein, which has a relative molecular mass of 99,000 (M r 99K). However, PNUTS alternative splicing leads to a break at position Lys318 generating a downstream premature stop codon, potentially allowing the generation of a M r 41K truncated protein. By immunoblot analysis, using an amino-terminal generated PNUTS antibody, we failed to detect a truncated expression product even following lncRNA-PNUTS overexpression in various cell lines ( Supplementary Fig. 2b ). Further, as analysed by polysome fractionation, lncRNA-PNUTS is observed only in the non-translating, monosomal fractions and not in the actively translating, polysomal fractions compared with PNUTS mRNA (Fig. 3a) , underlining its nontranslatability. Finally, endogenous lncRNA-PNUTS has a poly(A)+ tail ( Fig. 3b ) and is located in both the cytoplasmic and nuclear compartments as observed by cell fractionation, GFP tracking microscopy employing the MS2-Tag strategy and fluorescent in situ hybridization (FISH) analysis ( Fig. 3c,d and Supplementary Fig. 2c ).
lncRNA-PNUTS interacts with miR-205
Given the subcellular localization of lncRNA-PNUTS, we next explored its biological function as a presumed competing-endogenous RNA (ceRNA). By in silico analysis, we predicted 21 microRNAs (miRNAs) targeting at least five sites with a score higher than 0.6 (Supplementary Table 1 ). We focused on miRNA-binding sites most represented in the coding DNA sequence (CDS) of the cognate mRNA rather than in its 3 -UTR region to explore the intrinsic properties of the full-length lncRNA-PNUTS as a ceRNA. Among the ten miRNAs meeting this criterion, miR-205 was an obvious candidate due to its critical role in EMT and its high conservation among species 24 . We used quantitative real-time PCR to quantify the copy numbers of both miR-205 and lncRNA-PNUTS per cell since comparable levels are suggestive of ceRNA function (Fig. 3e ). FISH analysis ( Supplementary Fig. 2c ) demonstrates co-localization of miR-205 with lncRNA-PNUTS and not PNUTS mRNA. This suggests a preferential interaction of miR-205 with the lncRNA isoform, which was further confirmed by the use of biotinylated antisense probes ( Fig. 3g ).
Exon 12 BAT element probe (PNUTS-BAT * ) 5′-AAACCUUCUUCCCCAGAACCAG CACC ACCU UCUG AGGC AAUG GACG CAGA-3′ 
Biotin probe LncRNA-PNUTS harbours seven miR-205 sites, including one located in the 3 -UTR of the cognate PNUTS mRNA (Fig. 3f ). To ensure that the part including the first six miR-205-binding sites is functionally active, we cloned this portion, either wild type or mutated for the miRNA-205-binding sites, into the MS2-TRAP vector and validated the specific binding by an MS2-tagged RNA affinity purification strategy and by avidin-affinity pulldown of cellular lysates (Fig. 3h,i) . To investigate the decay mechanism(s) of lncRNA-PNUTS, we treated A549 cells with increasing concentrations of miR-205, which results in an expected decrease in ZEB1 and increase in E-cadherin expression levels, respectively; however, miR-205 levels have no significant impact on the level of lncRNA-PNUTS ( Fig. 3j ). Moreover, cycloheximide treatment of cells for up to 4 h considerably increases the expression of lncRNA-PNUTS, suggesting its sensitivity to nonsense-mediated mRNA decay ( Fig. 3k ).
lncRNA-PNUTS regulates EMT migration and invasion in vitro through its miR-205 interaction
Since lncRNA-PNUTS interacts with miRNA-205, a well-established regulator of ZEB proteins and of epithelial cell maintenance, we investigated its effects on ZEB expression and cell plasticity. We silenced endogenous lncRNA-PNUTS in mesenchymal and invasive MDA-231-LM2-4175 cells that express high levels of the lncRNA (Fig. 1e ) to test whether lncRNA-PNUTS could modulate cell plasticity. LncRNA-PNUTS silencing led to a significant decrease in cell invasion correlating with reduced vimentin expression (mesenchymal marker) and re-expression of epithelial marker E-cadherin concomitant to morphological changes (Fig. 4a ). To assess whether lncRNA-PNUTS generation is a prerequisite for TGFβ-mediated EMT, we treated A549 cells with ASO against the alternative splice site ( Fig. 2g ) and showed that it significantly impaired TGFβ-mediated EMT ( Supplementary  Fig. 3a,d,e ). This was confirmed using short interfering RNA (siRNA) specifically targeting lncRNA-PNUTS to prevent either TGFβmediated or hnRNP-E1-knockdown-mediated EMT ( Supplementary  Fig. 3b,c) . Moreover, the overexpression of lncRNA-PNUTS induced an EMT in both A549 and NMuMG as characterized by a morphological change from an epithelial-like, cobblestone phenotype to a more spindle-shaped mesenchymal phenotype, an E-cadherin/vimentin switch (Fig. 4b,c) , and an accompanying increase in the levels of the EMT transcription factors, ZEB1, ZEB2, SNAI1 and SNAI2 (Fig. 4d ). While the wild-type lncRNA-PNUTS induced an EMT associated with a downregulation of E-cadherin and upregulation of ZEB1, co-transfection with miRNA-205 as well as the overexpression of the miR-205-mutant form of the lncRNA-PNUTS abolished this effect (Fig. 4e,f) . The lncRNA-PNUTS controls both migration and invasion (Fig. 4g,h ) of A549 and NMuMG cells in a manner dependent on its miR-205-binding sites, and miR-205 overexpression is able to abolish this effect (Fig. 4h) . These observations were further validated by immunofluorescence ( Fig. 4i ).
lncRNA-PNUTS controls the miR-205/ZEB/E-cadherin axis
Using luciferase reporter assays we next validated the regulation of the miR-205/ZEB/E-cadherin axis by lncRNA-PNUTS. We first confirmed the binding of miR-205 to lncRNA-PNUTS by cloning the S3-S6-miR-205-binding sites of lncRNA-PNUTS as a 3 -UTR of the luciferase CDS ( Fig. 5a ) and demonstrated that co-transfection with miR-205 in A549 and NMuMG cells reduces luciferase expression with the wild type (WT), but not the mutated S3-S6-miR-205 construct (Fig. 5a) . Second, using a luciferase reporter construct whose stability is dependent on miR-205 binding (miR-205 microRNA recognition element (MRE)), we demonstrated that WT, but not the miR-205mutated-lncRNA-PNUTS, decreases miR-205 bioavailability (Fig. 5b) . Third, using constructs of Renilla fused to the ZEBs 3 -UTR ( Fig. 5c and Supplementary Fig. 4 ), we observed that WT lncRNA-PNUTS stabilized ZEBs 3 -UTR and this effect was partially abolished using the miR-205-mutated lncRNA or reversed by co-transfection with miR-205 mimics ( Fig. 5c and Supplementary Fig. 4 ). Importantly, no effects were observed on the ZEB1 3 -UTR mutated for its miR-205-binding site (Fig. 5c ). Last, using an E-cadherin (CDH1) promoter luciferase construct that contains either wild-type or mutant ZEBs-binding sites (E-boxes), we observed an ∼50% decrease of luciferase activity following lncRNA-PNUTS overexpression. This downregulation was partially rescued by co-transfection with miR-205 or abolished by using either the mutated lncRNA-PNUTS or the CDH1 promoter mutated for its E-boxes ( Fig. 5d ).
LncRNA-PNUTS regulates tumour implantation, growth and metastasis
Given the role of miR-205 in regulating mammary stem cell fate and tumorigenesis through EMT 25 , we investigated whether lncRNA-PNUTS contributes to these phenotypes. Utilizing the tridimensional, sphere-formation assay, we showed a significant increase in sphere formation of A549 and NMuMG cells induced by lncRNA-PNUTS dependent on its miR-205-binding sites (Fig. 6a,b ). Using limiting dilutions of MDA-468 cells in an in vivo fat pad injection assay, we observed that lncRNA overexpression resulted in an ∼80-fold increase of tumour-initiating cell number compared with the control (Fig. 6c ). Next, we FACS-sorted HMLE cells (Fig. 6d,e ) using CD24/CD44 to determine whether lncRNA-PNUTS is upregulated in stem cells. Although the CD24 − /CD44 + subpopulation (mesenchymal phenotype) is known to be highly enriched for tumour-initiating cells 26, 27 , we did not observe an upregulation of the lncRNA-PNUTS in this subpopulation compared with the CD24 + /CD44 − subpopulation (epithelial phenotype; Fig. 6f ). Nevertheless, overexpression of lncRNA-PNUTS in the epithelial subpopulation induced a significant decrease in the number of CD24 + /CD44 − cells and revealed a minor subpopulation of cells harbouring the CD24 − /CD44 + phenotype ( Fig. 6g and Supplementary Fig. 5a ). Additionally, silencing of lncRNA-PNUTS in MDA-231-LM2 cells led to increased expression of the CD24 epithelial marker ( Supplementary Fig. 5b ).
We next tested the effects of lncRNA-PNUTS on tumour progression in vivo and demonstrated that silencing of lncRNA-PNUTS in MDA-231-LM2 cells impairs tumour formation when injected orthotopically into mammary fat pads (Fig. 6h) . Moreover, lncRNA-PNUTS also contributes to in vivo metastasis as we observed a significant decrease of lung colonization in MDA-231-LM2 cells silenced for lncRNA-PNUTS compared with their scrambled-control counterparts (Fig. 6i ).
DISCUSSION
The discovery of lncRNAs as biologically relevant molecules has led to a rethinking of the central dogma of biology and unravelled new layers Vimentin DAPI S1 S2 S3 S5 S6 S4 S1 S2 S3 S5 S6 S4 lncRNA lncRNA S1-6M 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 10 1 10 0 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 Supplementary Table 2 . (i) Left, histopathological analysis of paraffin-embedded lung serial sections of mice injected in the mammary fat pad with MDA-231-LM2 expressing scrambled or lncRNA-PNUTS targeting shRNA. Haematoxylin and eosin (H&E) staining and immunostaining of Ki-67 protein was performed in serial lung sections to identify macro-and micro-metastases. Right, photographs of primary tumours and of a representative lung collected for each condition. Scale bars, 500 µM of cellular and molecular complexities. It is now well established that many genes can encode both mRNA and ncRNA. For instance, a large number of miRNAs and most of the small nucleolar RNA (snoRNAs) are processed from spliced introns. Furthermore, circular RNAs can be processed from introns or back-spliced exons 28 . Moreover, the existence of large numbers of bifunctional RNAs whose isoforms are regulated by alternative splicing, as described herein, was previously theorized and predicted on the basis of genome-wide data mining of alternative splicing events 29 . Here, we describe how under different cellular contexts, a gene, through alternative splicing, can encode for either an mRNA or a lncRNA and demonstrate the biological relevance of the generated lncRNA in targeting and sequestering miR-205 to ultimately regulate EMT (model Fig. 6e ).
Since alternative splicing and generation of lncRNA-PNUTS is an early event in TGFβ-mediated EMT, we postulate that lncRNA-PNUTS operates as a transient inhibitor of miR-205 to allow for the temporal upregulation of ZEBs and subsequent regulation of downstream EMT events. Indeed, ZEBs proteins are reciprocally linked in a feedback loop with the miR-200 family, each strictly controlling the expression of the other 30 . In this way, a transient, but nevertheless, strong decrease in miR-205 bioavailability, sufficient to activate the ZEB proteins, would allow for transcriptional repression of the miR-200 family or other miRNAs such as miR-183 or miR-203, thereby further stabilizing ZEB proteins and reinforcing the EMT process. Furthermore, the transient nature of the lncRNA-PNUTS allows for its early regulation of the miR-205/ZEB axis during EMT but is not sufficient to sustain a decrease in PNUTS mRNA and protein expression, thus allowing independent functions of the isoforms. Moreover, the fact that the lncRNA-PNUTS is upregulated in tumour samples compared with their non-tumour counterpart despite its transient functional role might be the result of tumour heterogeneity with regard to TGFβ signalling 31, 32 and that at any given time lncRNA-PNUTS is elevated in certain tumour cells. Finally, the alternative splicing of PNUTS is consistently accompanied by a decrease in the expression of the PNUTS pre-RNA. Since RNA splicing occurs co-transcriptionally, this decrease could be explained by the influence of transcriptional regulators pausing the RNAPII elongation complex to allow splicing to proceed on the alternative site 33 .
LncRNA-PNUTS is localized in both the cytoplasm and nucleus (Fig. 3c,d and Supplementary Fig. 2c ) and while its function as a ceRNA could be attributed to its cytoplasmic localization, its role in the nuclear compartment was not investigated herein. Nuclear biogenesis of lncRNA-PNUTS might explain its localization in the nucleus, although we speculate that it could also be involved in nuclear processes such as transcription or epigenetic regulation, as is the case for other previously described lncRNAs [34] [35] [36] . Moreover, we demonstrate that the transcriptional inhibitor ActD is a potent activator of the PNUTS alternative splicing through its effects on hnRNP E1 translocation from the nucleus to cytoplasm. Furthermore, lncRNA-PNUTS is upregulated by cycloheximide, a compound widely used to inhibit translation but also to test the sensitivity of RNAs to nonsensemediated mRNA decay by inhibiting the first round of translation 37 and which is also known to induce transport of hnRNPs into the cytoplasm 38 . On the basis of these results, we expect that any anti-tumour agents whose pharmacological properties block transcription might activate the alternative splicing of PNUTS. Given the role of EMT in drug resistance and the contribution of miR-205 in chemotherapy sensitivity [39] [40] [41] [42] , it will be of interest to evaluate the contribution of lncRNA-PNUTS in EMT-mediated drug resistance mechanisms.
However, it is of note that both PNUTS isoforms share miR-205 sites, raising the obvious question as to why the PNUTS mRNA does not itself serve to sequester miR-205 and regulate EMT. We postulate that the location of miRNA-binding sites in the CDS of the cognate mRNA, relative to those in the lncRNA, may affect miRNA binding.
As previously established, ribosomal hindrance could interfere with the ability of the miRNA to attach to its target site if it is located in the CDS 43 and this is supported by our data demonstrating preferential co-localization and binding of miR-205 with lncRNA-PNUTS. Additionally, the two PNUTS isoforms could have distinct secondary structures that might also explain the preferential binding of miR-205 to the lncRNA isoform. The fact that miR-205 binds weakly to the PNUTS mRNA, presumably to its site in the 3 -UTR, could also contribute to PNUTS protein stability during alternative splicing since the sponge activity of the lncRNA-PNUTS could counteract the inhibitory effect of the miR-205 initially occurring on the 3 -UTR of the PNUTS mRNA.
Collectively, our work confirms the key roles of lncRNAs and RNAbinding proteins in biological processes and human diseases. The study describes the generation and function of a lncRNA, and of an RNA-binding protein with which it associates, as key regulators of EMT and of the mesenchymal properties of tumour cells. Our in vivo data also demonstrate that modulation of lncRNA-PNUTS regulates the metastatic potential of tumour cells. Since most cancer-related mortalities result from metastatic disease and no mutations that are selective for metastases have been identified 3, 44, 45 , it is imperative to identify potential metastatic mediators for prognostic and therapeutic benefit. As such, the identification of both hnRNP E1 and lncRNA-PNUTS provides two additional targets that could potentially serve as predictive markers of metastasis and/or chemoresistance, as well as effective targets for anti-metastatic therapies.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3595 METHODS Cell culture, antibodies, primers and reagents. NMuMG, A549, MCF7, CaCo-2, HMLE, MCF10a and MDA-MB-468 cells were obtained from the American Type Culture Collection (ATCC), and the MDA-231 progression model was graciously provided by J. Massagué (Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, cat. no. SH30081.01, GE Healthcare Life Sciences) high glucose supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution (penicillin G, streptomycin, amphotericin B). MCF10a cells were obtained from ATCC and cultured in DMEM:F12 supplemented with 5% horse serum, 0.5 µg ml −1 hydrocortisone, 10 µg ml −1 insulin, 20 ng ml −1 epidermal growth factor, 100 ng ml −1 cholera toxin and 1% antibiotic/antimycotic. All cells were cultured in a 37 • C, 5% CO 2 incubator. TGFβ2 was a generous gift from Genzyme Corporation. Antibody dilutions, company names, catalogue numbers and clone numbers and their respective dilutions are listed below. Puromycin and G418 were purchased from InvivoGen. Cycloheximide and actinomycin D were purchased from Sigma. Site-directed mutagenesis was performed using a site-directed mutagenesis kit from Life Technologies as described by the manufacturer. Mouse monoclonal anti-Ecadherin (clone 4A2, cat. no. 14472, 1:2,000 dilution), rabbit monoclonal anti-Ecadherin (clone 24E10, cat. no. 3195, 1:2,000 dilution), rabbit monoclonal antivimentin (clone D21H3, cat. no. 5741, 1:2,000 dilution), rabbit monoclonal anti-ZEB1 (clone D80D3, cat. no. 3396, 1:1,000 dilution), rabbit monoclonal anti-Ki-67 (clone D2H10, cat. no. 9027, 1:1,600 dilution) and rabbit polyclonal anti-PARP (cat. no. 9542, 1:2,000 dilution) were purchased from Cell Signaling Technology. Mouse monoclonal anti-GAPDH (clone 6C5, cat. no. sc32233, 1:5,000 dilution) and mouse monoclonal anti-HSP90 (clone F-8, cat. no. sc-13119, 1:2,000 dilution) were purchased from Santa Cruz Biotechnology. Rabbit monoclonal anti-vimentin (clone EPR3776, cat. no. Ab92547, 1:2,000 dilution) was purchased from Abcam. Rabbit polyclonal anti-PNUTS (cat. no. 24450-1-AP, 1:1,000 dilution) was purchased from Proteintech. Mouse monoclonal anti-hnRNPE1 (clone 1G2 cat. no. H00005093-M01, 1:1,000 dilution) was purchased from Abnova. Mouse monoclonal anti-GFP (clones 7.1 & 13.1, cat. no. 11 814 460 001, 1:500 dilution) was purchased from Roche. The primers used in PCR analysis were purchased from IDT and are as follows:
3 Transfections. All cell transfections were carried out using 5 µg DNA (or the specified amount) per 8 ml of medium with cells at 70% confluence cultured in 100 mm plates. The transfection reagent Lipofectamine (ThermoFisher Scientific) was used according to the protocol provided by the manufacturer.
Transfection of small interfering RNA. Two specific sequences were designed across the new exon-exon junction generating the lncRNA-PNUTS. The sequences were submitted to a BLAST search against the human genome to ensure the specificity of the siRNA to the targeted sequence. Two corresponding scramble duplexes, which do not recognize any sequence in the human genome, were used as controls. The sense and antisense strands were then annealed to obtain duplexes with identical 3 overhangs. For transfection of the siRNA duplexes, 75,000 cells were seeded in a six-well plates containing 2 ml of culture medium. Twenty-four hours after the seeding, the cells were transfected by phosphate calcium precipitation by adding in each well 200 µl of a mixture containing the siRNA duplexes, 140 mM NaCl, 0.75 nM Na 2 HPO 4 , 6 nM glucose, 5 mM KCl, 25 mM HEPES and 125 mM CaCl 2 . Twenty-four hours after transfection, the cells were extensively washed with PBS and incubated for 48 h in culture medium before they were harvested for PCR with reverse transcription (RT-PCR) analyses and western blotting analyses.
ASO oligonucleotide design and usage. Antisense oligonucleotide (IDT) was designed against the splicing site used to generate the lncRNA-PNUTS to prevent its usage. The oligonucleotide consists of modified 2 -O-methyl phosphothioate oligonucleotide where each ribose and each phosphate group was modified by a 2 -O-methyl modification or a single sulfur, respectively (sequence: mG * mU * mG * mG * mU * mG * mC * mU * mG * mG * mU * mU * mC * mU * mG). Cells were transfected with the indicated amount of the oligonucleotide 2 h prior to treatment of the cells. For the reverse transcription step, the RNAs were pre-heated in the reaction mix (65 • C/5 min, 75 • C/2 min, 35 • C/30 s) prior to addition of the reverse transcriptase and RT reaction.
Polysome profiling. Cells were extracted in TMK 100 buffer (10 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1% (v/v) Triton X-100, 0.5% deoxycholate, 2 mM dithiothreitol, 100 µg ml −1 cycloheximide) and then supernatant was collected by centrifugation (14,000 r.p.m. (12,000g ), 10 min). Cell extracts were layered onto sucrose gradients (10-50%) and centrifuged at 35,000 r.p.m. in a SW40Ti rotor for 3 h at 4 • C. Fractions were collected using a density gradient fractionation system (Teledyne Isco) and then RNA was isolated using Trizol. Monosomal and polysomal fractions were determined by analysis of 18S and 28S rRNA levels using denaturing agarose gel electrophoresis.
Modified Boyden chamber invasion assay. Invasion across a basement membrane was performed using BD BioCoat Matrigel Invasion Chambers (BD Biosciences) as per the manufacturer's instructions. Briefly, a total of 10 5 cells were placed in the upper compartment of the invasion chamber (BD BioCoat Matrigel Invasion Chamber, BD Biosciences) for 24 h at 37 • C. Non-invading cells were removed with a swab and the filters were then fixed in methanol and stained with crystal violet. Quantification of the invasion assay was performed by spectrophotometry after resuspension of the stain.
Western blot analysis. Western blot analysis was performed by standard SDS-PAGE. Whole-cell lysates were prepared from 2-5 × 10 6 cells in 300 µl of lysis buffer (20 mM Tris, pH 7.4, 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 1 mM Na 3 VO 4 and protease inhibitors). Lysates were sonicated and clarified by centrifugation at 4 • C for 10 min in a Beckman tabletop microcentrifuge at maximum speed. Typically, 5-20 µg of whole-cell lysates were separated on 10 or 12% acrylamide minigels and transferred to Immobilon-P membrane (Millipore). The membrane was blocked for 1 h in wash buffer (PBS containing 0.1% Tween 20) containing 5% non-fat dry milk followed by an overnight incubation with primary antibody diluted in the same blocking buffer. After extensive washing, the blot was incubated with secondary antibody for 1 h in blocking buffer, washed, and processed using the ECL+ Western blotting detection system (Amersham Biosciences).
Immunofluorescence, FISH and imaging. For immunofluorescence, cells were fixed for 15 min in PBS containing 3.7% (w/v) paraformaldehyde, followed by permeabilization with 0.2% (w/v) Triton X-100. Cells were then incubated for 1 h in 3% BSA and incubated overnight with primary antibody at 4 • C. Then cells were incubated with secondary antibodies conjugated with Alexa Fluor (Life Technologies) at room temperature for 1 h followed by three washes with PBS before analysis with the FV10i confocal laser scanning microscope (Olympus). For FISH analysis, cells were fixed for 15 min in PBS containing 3.7% (w/v) paraformaldehyde, then slides were incubated overnight at 37 • C in hybridization solution (10% formamide, 2× SSC, 10% dextran sulfate (w/v), 10 µM each probe, labelled with ATTO-488,590 and 649 respectively, IDT). Cells were then washed twice for 30 min at 37 • C with 10% formamide in 2× SSC. DAPI was applied during the second wash. Cells were then rinsed twice with 2× SSC before imaging in 2× SSC buffer.
Immunohistochemistry. Formalin-fixed, paraffin-embedded sections were deparaffinized in xylene, rehydrated in alcohol, and processed as follows. Sections were incubated with target retrieval solution (Dako) in a steamer for 45 min followed by 3% hydrogen peroxide solution for 10 min and protein block (Dako) for 20 min at room temperature. Sections were incubated overnight in a humid chamber at 4 • C with antibody against Ki-67 purchased from Cell Signaling Technology (clone D2H10, cat. no. 9027, 1:1,600 dilution) followed by biotinylated secondary antibody (Vector Laboratories) for 30 min and ABC reagent for 30 min. Immunocomplexes of horseradish peroxidase were visualized by DAB reaction (Dako), and sections were counterstained with haematoxylin before mounting. Micrographs of stained sections were taken using a Leica DMIL LED microscope with an Amscope camera and acquisition software.
Immunoprecipitation assays and biotin pulldown. MS2-TRAP immunoprecipitation assays were performed as described previously 46 . Immunoprecipitated RNA was isolated from beads by addition of Trizol, followed by RT-PCR as described above.
